Samrat Pharmachem Limited

🔴 Bear CaseWhat could go wrong?

1. Margins are being competed away
   EBITDA margin has fallen from 7.8% to -0.7%. If the trend continues, profit falls even on flat sales — and margin decline rarely reverses quickly.
2. Returns on shareholder capital are falling
   ROE has dropped from 26.3% to -4.9%. Each rupee of equity earns less than it did, so profit growth increasingly depends on raising more capital rather than on the existing base working harder.
3. Earnings are hard to forecast
   Profit has swung sharply from year to year, so any single year — good or bad — is a weak guide to the next. Cyclical earnings deserve lower multiples for that reason.
4. Size brings its own risk
   Micro Cap businesses are thinly traded, so exits are harder in a falling market and single events move the price more than they would for a larger company.
5. Several serious flags at once
   3 high-severity checks triggered. Individually each has an explanation; together they raise the chance that something structural is wrong rather than a one-off.